相关实验视频

Updated: Sep 18, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

在复发性或耐受性中枢神经系统淋巴瘤中,基于奥雷拉布鲁丁尼的个性化治疗方案的有效性

Yuchen Wu¹, Xuefei Sun¹, Liwei Lv²

¹Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Frontiers in neurology

|June 20, 2025

概括

基于奥雷拉布鲁替尼的疗法 (Ore-MIED/Ore-MTD) 在复发性/耐药性中枢神经系统淋巴瘤中显示出高响应率. 这项研究表明,这些治疗方法对于难以治疗的脑淋巴瘤患者来说是有效和安全的.

科学领域:

神经瘤学神经瘤学
血液学恶性瘤是什么
药理学药理学是指药理学的学科.

背景情况:

复发性或难治性中枢神经系统淋巴瘤 (rrCNSL) 是一个重要的临床挑战,治疗选择有限.
布鲁顿的氨酸激酶抑制剂 (BTKi) 已成为B细胞恶性瘤的有前途的治疗类.
第二代BTKiOrelabrutinib在脑脊液中具有很高的透率,使其成为中枢神经系统向治疗的潜在候选者.

研究的目的:

评估与 rrCNSL.患者的化疗方案结合的欧雷拉布鲁丁尼的疗效和安全性.
为了比较两种不同的基于Orelabrutinib的治疗策略之间的结果:Ore-MIED和Ore-MTD.

主要方法:

对37名被诊断为复发性或耐火性中枢神经系统扩散性大B细胞淋巴瘤的患者进行了回顾性分析.
患者接受了奥雷拉布鲁替尼,高剂量甲上,伊福斯法米德,埃托波西德和德克萨米他 (Ore-MIED) 或奥雷拉布鲁替尼,高剂量甲上,泰莫索洛米德和德克萨米他 (Ore-MTD).

主要成果:

综合队列的整体应答率 (ORR) 为89.2%,其中51.4%实现完全缓解 (CR),37.8%实现部分缓解 (PR).
无进展生存期 (PFS) 中位数为7.0个月,Ore-MTD (5.0个月) 和Ore-MIED (13.0个月) 组之间没有统计学上显著的差异 (p=0.29).
平均整体存活率 (OS) 尚未达到,这表明持久的反应和有希望的长期结果.

结论:

基于奥雷拉布鲁替尼的疗法 (Ore-MIED/Ore-MTD) 在患有 rrCNSL.L 的患者中显示出显著的有效性和有利的安全性.
这些治疗策略为rrCNSL患者提供了可行的治疗选择,包括那些先前广泛接受治疗的患者.
这些发现支持在中枢神经系统淋巴瘤的管理中继续调查奥雷拉布鲁丁尼.

关键词:

布鲁顿的铁氨基激酶抑制剂是Bruton的铁氨基激酶抑制剂.中枢神经系统淋巴瘤中枢神经系统淋巴瘤甲基特雷克萨酸盐的使用方法还有一种是labrutinib.复发或耐火性复发或耐火性

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...